CY1106541T1 - Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης - Google Patents

Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης

Info

Publication number
CY1106541T1
CY1106541T1 CY20071100559T CY071100559T CY1106541T1 CY 1106541 T1 CY1106541 T1 CY 1106541T1 CY 20071100559 T CY20071100559 T CY 20071100559T CY 071100559 T CY071100559 T CY 071100559T CY 1106541 T1 CY1106541 T1 CY 1106541T1
Authority
CY
Cyprus
Prior art keywords
cox
nsaid
mrna
synthesis
nsaids
Prior art date
Application number
CY20071100559T
Other languages
Greek (el)
English (en)
Inventor
William J. Wechter
Original Assignee
Loma Linda University Medical Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106541(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loma Linda University Medical Centre filed Critical Loma Linda University Medical Centre
Publication of CY1106541T1 publication Critical patent/CY1106541T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20071100559T 1998-09-03 2007-04-26 Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης CY1106541T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (1)

Publication Number Publication Date
CY1106541T1 true CY1106541T1 (el) 2012-01-25

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100559T CY1106541T1 (el) 1998-09-03 2007-04-26 Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης

Country Status (13)

Country Link
US (1) US6472433B2 (https=)
EP (1) EP1143958B8 (https=)
JP (1) JP2002524415A (https=)
CN (1) CN1391470A (https=)
AT (1) ATE353010T1 (https=)
AU (1) AU6026099A (https=)
CA (1) CA2342628C (https=)
CY (1) CY1106541T1 (https=)
DE (1) DE69933049T2 (https=)
DK (1) DK1143958T3 (https=)
ES (1) ES2281981T3 (https=)
PT (1) PT1143958E (https=)
WO (1) WO2000013684A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
ATE283048T1 (de) 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Also Published As

Publication number Publication date
DE69933049T2 (de) 2007-10-04
ATE353010T1 (de) 2007-02-15
EP1143958B1 (en) 2007-01-31
EP1143958A2 (en) 2001-10-17
ES2281981T3 (es) 2007-10-01
JP2002524415A (ja) 2002-08-06
CA2342628C (en) 2009-07-07
WO2000013684A2 (en) 2000-03-16
US6472433B2 (en) 2002-10-29
US20010012849A1 (en) 2001-08-09
EP1143958B8 (en) 2007-05-23
DE69933049D1 (de) 2006-10-12
EP1143958A3 (en) 2002-08-21
PT1143958E (pt) 2007-04-30
CN1391470A (zh) 2003-01-15
WO2000013684A3 (en) 2002-05-30
CA2342628A1 (en) 2000-03-16
DK1143958T3 (da) 2007-04-10
AU6026099A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
MX9308199A (es) Inhibidores de enzima.
NO954878L (no) Pyrrolderivater
DE69824622D1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
TR199801530T2 (xx) VEGF �nhibit�rleri olarak kinazolin t�revleri.
DE69706642D1 (de) Pyridylfuran- und Pyridylthiphenderivate und deren pharmazeutische Verwendung
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
BR0308222A (pt) Terapias de combinação para tratar células deficientes em metiltioadenosina fosforilase
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
NO985232L (no) Androstenderivater
DK1370260T3 (da) Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
Atkinson et al. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
DK0814792T3 (da) Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase
Ahmad et al. Nitric oxide synthase and skin tumor promotion
NO985676D0 (no) Forbindelser med colchicinstruktur, deres anvendelse som legemidler og blandinger som inneholder dem
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb